drugset / Trial / NCT06596356

A Mass Balance Study of TS-172 in Healthy Adult Subjects

NCT06596356

Phase 1 Completed 6 enrolled Taisho Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

To assess the plasma pharmacokinetics, the routes extent of elimination, and the metabolites of TS-172 after single oral dose of \[14C\] TS-172 in Japanese healthy male subjects. To assess the safety of single oral dose of \[14C\] TS-172 in Japanese healthy male subjects.

Timeline

Start
2024-09-26
Primary completion
2024-10-28
Completion
2024-10-28

Drugs

EvaluationDrugModalityDoseRoute
Subject TS-172 Unknown 30 mg Oral

Indications

No indication recorded.